Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Biofrontera ( (BFRI) ) is now available.
On June 30, 2025, Biofrontera Inc. announced a significant restructuring of its relationship with Biofrontera AG, acquiring all U.S. rights to Ameluz® and RhodoLED® backed by an $11 million investment led by existing investors. This agreement reduces the royalty rate on Ameluz® sales, aiming to drive the company towards profitability and strengthen its presence in the U.S. dermatology market. The restructuring allows Biofrontera Inc. to assume full control over manufacturing, regulatory, and commercial responsibilities in the U.S., aligning long-term interests with Biofrontera AG through a 10% equity stake. The move is expected to enhance operational agility and support the company’s growth strategy, including an upcoming FDA submission for treating superficial basal cell carcinoma.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s overall stock score reflects significant financial challenges, including a negative P/E ratio and reliance on external financing. Technical indicators do not suggest a clear trend, and recent corporate events raise compliance concerns. Despite some operational improvements, the company’s financial instability and compliance issues weigh heavily on the overall score.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of actinic keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers. Biofrontera Inc. also conducts clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.
Average Trading Volume: 144,626
Technical Sentiment Signal: Sell
Current Market Cap: $5.68M
For a thorough assessment of BFRI stock, go to TipRanks’ Stock Analysis page.